Seelos therapeutics announces positive in vivo data demonstrating down-regulation of snca mrna and protein expression from a gene therapy study of sls-004 utilizing crispr-dcas9 for parkinson's disease pathology

New york, july 7, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced positive in vivo data demonstrating down-regulation of snca mrna and protein-expression from a study of sls-004 in an in-vivo rodent model utilizing crispr-dcas9 gene therapy technology. a single dose of sls-004 produced a therapeutically desirable 27% reduction on snca mrna and a 40% reduction in snca protein expression.
SEEL Ratings Summary
SEEL Quant Ranking